Age, median (range; years) |
58 (41–69) |
Sex, n (%) |
Male |
27 (90.0) |
Female |
3 (10.0) |
Smoker, n (%) |
No |
16 (53.3) |
Former, ≤10 pack-year |
1 (3.3) |
Former, >10 pack-year |
13 (43.3) |
Alcohol use history, n (%) |
Ever |
21 (70.0) |
Never |
9 (30.0) |
HPV status (oropharynx), n (%) |
Positive |
5 (38.5) |
Negative |
8 (61.5) |
Primary tumor site, n (%) |
Tonsil |
12 (40.0) |
Soft palate |
1 (3.3) |
Larynx |
6 (20.0) |
Hypopharynx |
9 (30.0) |
Base of tongue |
2 (6.7) |
Pretreatment clinical T-stage, n (%) |
T1 |
1 (3.3) |
T2 |
7 (23.3) |
T3 |
14 (46.7) |
T4 |
8 (26.7) |
Pretreatment clinical N-stage, n (%) |
N0 |
3 (10.0) |
N1 |
4 (13.3) |
N2 |
18 (60) |
N3 |
5 (16.7) |
AJCC stage, n (%) |
II |
4 (13.3) |
III |
4 (13.3) |
IV |
22 (73.3) |
IVA |
17 (56.7) |
IVB |
5 (16.7) |
PD-L1 combined positive score, n (%) |
<1 |
2 (6.7) |
1–19 |
12 (40.0) |
≥20 |
8 (26.7) |
Not available |
8 (26.7) |